Organic cation transporter pharmacogenomics and drug–drug interaction

Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions

(2010) Giuliano Ciarimboli et al.   AMERICAN JOURNAL OF PATHOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

(2010) Zhi-Jun Wang et al.   Pharmacogenetics and Genomics

Pharmacogenomics of membrane transporters: past, present and future

(2010) Sook Wah Yee et al.   PHARMACOGENOMICS

Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2

(2009) Yuko Tanihara et al.   BIOCHEMICAL PHARMACOLOGY

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

(2009) K K Filipski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

(2009) K. Zhou et al.   DIABETES

In vitroevidence for the role of OATP and OCT uptake transporters in drug–drug interactions

(2009) Jürgen Kindla et al.   Expert Opinion on Drug Metabolism & Toxicology

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Transport of Lamivudine [(-)- -L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3

(2009) G. Minuesa et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease

(2009) David-Alexandre Trégouët et al.   NATURE GENETICS

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

(2009) Ying Chen et al.   Pharmacogenetics and Genomics

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1

(2008) I. Bachmakov et al.   DIABETES

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection

(2008) N. Jung et al.   DRUG METABOLISM AND DISPOSITION

Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs

(2008) Anne T Nies et al.   Expert Opinion on Drug Metabolism & Toxicology

Interactions of Organic Anion Transporters and Organic Cation Transporters With Mycotoxins

(2008) Kittipong Tachampa et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Multiple newly identified loci associated with prostate cancer susceptibility

(2008) Rosalind A Eeles et al.   NATURE GENETICS

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3in vitroand implications for drug–drug interactions

(2008) K.-I. Umehara et al.   XENOBIOTICA

Role of transport proteins in drug discovery and development: a pharmaceutical perspective

(2008) A. Ayrton et al.   XENOBIOTICA